NEW YORK, Jan. 9, 2017
NEW YORK, Jan. 9, 2017 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Agile Therapeutics, Inc. ("Agile Therapeutics" or the "Company") (NASDAQ: AGRX) concerning whether the board has breached its fiduciary duties to shareholders.
On January 3, 2017, the Company disclosed information related to the Phase 3 study of its product candidate, Twirla, a combined hormonal contraceptive patch. The study failed to meet standards achieved by other currently-marketed contraceptive patches and over half of the subjects opted to discontinue their participation in the study.
Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.
If you own Agile Therapeutics shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/harwood-feffer-llp-announces-investigation-of-agile-therapeutics-inc-300388152.html
SOURCE Harwood Feffer LLP